The Oncology Institute, Inc. - Common Stock (TOI)
Healthcare › Services-Offices & Clinics of Doctors of Medicine
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -8.8%
- Revenue growing at 28% annually
The Oncology Institute, Inc. - Common Stock (TOI) is a Healthcare company operating in Services-Offices & Clinics of Doctors of Medicine, listed on the NASDAQ , with a market capitalisation of $259 million . Key value metrics: Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
The Oncology Institute, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, TOI shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -8.8% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.31.
StockPik's composite Value Score for TOI is 51/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
TOI shows revenue growing at 28% year-over-year, with earnings growing at 6%.